Expert advice on novel coronavirus vaccination in patients with malignant tumors

doi:10.19871/j.cnki.xfcrbzz.2022.02.001

Abstract

Abstract: Since SARS-CoV-2 infection remains to be a global pandemic, effective vaccination strategies were urgent to reduce the infection rate of SARS-CoV-2, attenuate the progress of the disease, and decrease the mortality after infection, which is particularly important for immunosuppressed patients. However, the efficacy and safety of SARS-CoV-2 vaccination in patients with malignant tumor are not well investigated in China, therefore, leading to a low SARS-CoV-2 vaccination coverage in patients with malignant tumor. According to the most recent researches and clinical treatment demands of SARS-CoV-2 vaccination for patients with malignant tumors, we summarized a detailed SARS-CoV-2 vaccination regimen for malignant tumors patients with different types of tumor, distinct anticancer treatment plan, as well as specialized the disease condition, so as to improve SARS-CoV-2 vaccines coverage, effectively protect patients, and reduce the susceptibility, severity and mortality of SARS-CoV-2 infection in patients with malignant tumors.

Key words: Malignant tumor, Severe acute respiratory syndrome coronavirus 2, Vaccination, Expert advice

Yuan Jing, Tan Xiaohua, Wang Fuxiang, Wang Lyuhua, Lu Hongzhou. Expert advice on novel coronavirus vaccination in patients with malignant tumors[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(2): 1-5.

References

[1] 郝鹏飞,许汪,杜寿文,等.冠状病毒起源、受体及新型冠状病毒检测与疫苗最新研究进展[J/CD].新发传染病电子杂志,2020,5(2):74-78.
[2] 李倩,卢洪洲.新型冠状病毒疫苗研究最新进展[J/CD].新发传染病电子杂志,2020,5(4):268-273.
[3] SUNG H, FERLAY J, SIEGEL RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin, 2021, 71(3):209-249.
[4] LIANG W, GUAN W, CHEN R, et al.Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21: 335-337.
[5] COREY L, BEYRER C, COHEN MS, et al.SARS-CoV-2 variants in patients with immunosuppression[J]. N Engl J Med, 2021, 385(6):562-566.
[6] DAI M, LIU D, LIU M, et al.Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak[J]. Cancer Discov, 2020, 10(6):783-791.
[7] SHAH V, KOKO T, ZUCKERMAN M, et al.Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience[J]. Br J Haematol, 2020, 190(5):e279-e282.
[8] YANG K, SHENG Y, HUANG C, et al.Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study[J]. Lancet Oncol, 2020, 21(7):904-913.
[9] ROBILOTTI EV, BABADY NE, MEAD PA, et al.Determinants of COVID-19 disease severity in patients with cancer[J]. Nat Med, 2020, 26(8):1218-1223.
[10] GIANNAKOULIS VG, PAPOUTSI E, SIEMPOS, II.Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data[J]. JCO Glob Oncol, 2020, 6:799-808.
[11] KUDERER NM, CHOUEIRI TK, SHAH DP, et al.Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study[J]. Lancet, 2020, 395(10241):1907-1918.
[12] BERTUZZI AF, CICCARELLI M, MARRARI A, et al.Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy[J]. Br J Cancer, 2021, 125(3):358-365.
[13] WU JT, LA J, BRANCH-ELLIMAN W, et al.Association of COVID-19 Vaccination With SARS-CoV-2 Infection Patients With Cancer: A US Nationwide Veterans Affairs Study[J]. JAMA Oncol, 2022, 8(2):281-286.
[14] THAKKAR A, GONZALEZ-LUGO JD, GORADIA N, et al.Seroconversion rates following COVID-19 vaccination among patients with cancer[J]. Cancer Cell, 2021, 39(8):1081-1090.
[15] HERISHANU Y, AVIVI I, AHARON A, et al.Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia[J]. Blood, 2021, 137(23):3165-3173.
[16] GRANNIS SJ, ROWLEY EA, ONG TC, et al.Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2B.1.617.2(Delta) Variant Predominance-Nine States, June-August 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(37):1291-1293.
[17] 廖康生,卢洪洲.新型冠状病毒奥密克戎变异株的研究进展:对其科学防控措施的启示[J/CD].新发传染病电子杂志,2022,7(1):1-5.
[18] 中华人民共和国国家卫生健康委员会疾病预防控制局. 新冠病毒疫苗接种技术指南(第一版)[J].中国病毒病杂志, 2021, 11(3):161-162.
[19] 徐若男,聂建云,王涛, 等. 乳腺癌患者新冠疫苗接种中国专家共识[J]. 传染病信息, 2021, 34(6):481-484.
[20] NATIONAL COMPREHENSIVE CANCER NETWORK. Cancer and COVID-19 Vaccination (V6.0)[EB/OL]. [2022-04-27].https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v5-0.pdf?sfvrsn=b483da2b_114.
[21] EUROPEAN CANCER PATIENT COALITION. 癌症病人新冠疫苗接种指南(中文版)[EB/OL]. https://ecpc.org/news-events/癌症病人新冠疫苗接种指南(中文版).
[22] DESAI A, GAINOR JF, HEGDE A, et al.COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials[J]. Nat Rev Clin Oncol, 2021, 18(5):313-319.
[23] VIVEK N, KERRI JS, EVAN CL, et al.Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer[J]. Cancer Cell, 2022, 40(1):103-108.
[24] 张哲,马莹,董妥,等. 新型冠状病毒变异株对新冠病毒疫苗免疫效力的影响[J]. 国际免疫学杂志,2021, 44(5): 487-492.
[25] NATIONAL COMPREHENSIVE CANCER NETWORK. COVID-19 resources[EB/OL].[2021-11-19]. https://www.nccn.org/covid-19.
[26] AMERICAN SOCIETY OF HEMATOLOGY. ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients: frequently asked questions[EB/OL].[2021-11-20]. https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients.
[27] AMERICAN SOCIETY OF HEMATOLOGY. General principles of COVID-19 vaccines for immunocompromised patients[EB/OL].[2021-12-24].https://www.hematology.org/covid-19.